Skip to main content
. 2021 Oct 19;3(4):537–546. doi: 10.1016/j.jaccao.2021.08.009

Figure 2.

Figure 2

Diagnoses of ATTRwt Amyloidosis by Region

Diagnoses in the United States versus the rest of the world in THAOS (the Transthyretin Amyloidosis Outcomes Survey) are shown by year. Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) diagnoses in the United States in THAOS increased steadily from 2005 to 2017, after which diagnoses appeared to decrease. In the rest of the world, ATTRwt amyloidosis diagnoses increased less steadily, but continued upward in 2018 and 2019. ∗Year of diagnosis missing for 45 patients in the United States and 42 in the rest of the world.